Narendranath Epperla

Hematology
2000 Cir of Hope Dr
Salt Lake City, UT 84112

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 213 publications

Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

Journal: Blood immunology & cellular therapy
Published: July 08, 2026

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis.

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis.

Journal: American journal of hematology
Published: June 26, 2026

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Journal: Blood cancer discovery
Published: May 18, 2026

CLO26-125: Treatment Intensity of Dose-Adjusted EPOCH-R and Its Relationship to Outcomes in Aggressive B-Cell Non-Hodgkin Lymphoma.

CLO26-125: Treatment Intensity of Dose-Adjusted EPOCH-R and Its Relationship to Outcomes in Aggressive B-Cell Non-Hodgkin Lymphoma.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026

CLO26-125: Treatment Intensity of Dose-Adjusted EPOCH-R and Its Relationship to Outcomes in Aggressive B-Cell Non-Hodgkin Lymphoma.

CLO26-125: Treatment Intensity of Dose-Adjusted EPOCH-R and Its Relationship to Outcomes in Aggressive B-Cell Non-Hodgkin Lymphoma.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 01, 2026

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas.

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas.

Journal: Journal of hematology & oncology
Published: March 09, 2026

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.

Journal: Blood cancer journal
Published: March 06, 2026

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Journal: Research square
Published: February 23, 2026

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Journal: Blood advances
Published: February 23, 2026

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Journal: Blood advances
Published: February 23, 2026

Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models.

Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models.

Journal: Biomarker research
Published: February 13, 2026

Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate.

Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: February 04, 2026
Showing 1-12 of 213

Last Updated: 09/26/2026